At a glance
ClinicalIndex Comparison Record- ✓Cohort 1: Rising PSA (≤5 ng/mL, at least 3 measurements 1 week apart) with castrate testosterone levels (<50 ng/dL) maintained by LHRH agonist or bilateral orchiectomy, without metastatic disease
- ✓Cohort 1: No prior chemotherapy for prostate cancer or other indications within 2 years of study entry
- ✓Cohort 2: One prior docetaxel-based chemotherapy regimen
- ✓Cohort 2: Metastatic prostate cancer with bone or soft-tissue disease
- ✕Unable to swallow oral medication
- ✕Serious heart condition
- ✕Currently receiving another anti-cancer therapy
- ✕Received another experimental drug within the last 30 days
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy
In Brief
A Phase 2 clinical trial evaluating enzastaurin for Prostate Cancer. Completed, enrolled 73 participants across 11 sites.
Detailed Summary
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive disease without clinical or radiographic evidence of metastatic disease. Cohort 2 - participants with androgen-independent metastatic prostate cancer (documented bone or soft tissue metastases) with rising PSA, clinical, radiographic disease progression following one prior docetaxel-based regimen
Study Details
Timeline
Interventions
Administered orally